Pancreatic cancer is one of the leading causes for cancer-related deaths in the United
States. Majority of patients present with unresectable or metastatic disease. For those that …

Thanks to the development of modern chemotherapeutic regimens, survival after surgery for
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …

PURPOSE Preoperative chemoradiotherapy may improve the radical resection rate for
resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven …

Objective: This study was performed to determine whether neoadjuvant treatment increases
survival in patients with BRPC. Summary Background Data: Despite many promising …

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …

Purpose To provide evidence-based recommendations to oncologists and others on
potentially curative therapy for patients with localized pancreatic cancer. Methods ASCO …

Purpose We conducted a phase II trial to assess the outcomes of patients who received
preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for …

During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent
chemoradiotherapy has improved cancer care dramatically. Significant contributions have …

BACKGROUND: Locally advanced pancreatic cancer patients have limited options for
disease control. Local ablation technologies based on thermal damage have been used but …

Background R0 resection rates (complete tumour removal with negative resection margins)
in pancreatic cancer are 70–80 per cent when a 0-mm margin is used, declining to 15–24 …